(NASDAQ: ALT) Altimmune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.23%.
Altimmune's earnings in 2026 is -$88,093,000.On average, 11 Wall Street analysts forecast ALT's earnings for 2026 to be -$161,689,996, with the lowest ALT earnings forecast at -$211,597,848, and the highest ALT earnings forecast at -$140,670,687. On average, 7 Wall Street analysts forecast ALT's earnings for 2027 to be -$144,728,870, with the lowest ALT earnings forecast at -$249,838,423, and the highest ALT earnings forecast at -$25,948,962.
In 2028, ALT is forecast to generate $393,682,818 in earnings, with the lowest earnings forecast at -$248,563,738 and the highest earnings forecast at $1,506,405,508.